Alvameline Explained

Alvameline (Lu 25-109) is a M1 receptor agonist and M2/M3 receptor antagonist[1] that was under investigation for the treatment of Alzheimer's disease, but produced poor results in clinical trials[2] and was subsequently discontinued.

See also

Notes and References

  1. Sánchez C, Arnt J, Didriksen M, Dragsted N, Moltzen Lenz S, Matz J . In vivo muscarinic cholinergic mediated effects of Lu 25-109, a M1 agonist and M2/M3 antagonist in vitro . Psychopharmacology . 137 . 3 . 233–240 . June 1998 . 9683000 . 10.1007/s002130050615 . 2009-12-03 . dead . 20740372 . https://web.archive.org/web/20001002164635/http://link.springer.de/link/service/journals/00213/bibs/8137003/81370233.htm . 2000-10-02 .
  2. Sramek JJ, Forrest M, Mengel H, Jhee SS, Hourani J, Cutler NR . A bridging study of LU 25-109 in patients with probable Alzheimer's disease . Life Sciences . 62 . 3 . 195–202 . 1998 . 9488097 . 10.1016/S0024-3205(97)01087-4 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Alvameline".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.